The Myeloma2018 meeting was held in San Diego, on 7-9 September. The meeting provided an opportunity for leading experts in multiple myeloma (MM) to present and discuss the latest data and advancements in the field.
Treatment regimens for MM have continued to improve in recent years, as a result of extensive research in the field, leading to further developments in novel drug targets, drug combinations and biomarkers, all of which were featured during the Myeloma2018 meeting!
Clinical genetics, measurable residual disease (MRD), immunotherapy and drug resistance were also among the topics thoroughly discussed by the delegates. VJHemOnc are pleased to share exclusive, on-demand webcast presentations from the meeting.
Watch all of our webcasts here to stay up-to-date on current advances in myeloma presented at Myeloma2018.
Session I: Clinical Genomics
Suzanne Trudel, MD, FRCPC
Ola Landgren, MD, PhD
Angela Dispenzieri, MD
VJHemOnc is proud to share exclusive roundtable discussions from Myeloma2018, bringing you deeper insights on the topics from the meeting.
Watch all of our expert-led discussions and interviews now on VJHemOnc, and experience the debates and conversations on-demand. Highlights from the meeting include defining the genomics of myeloma in the development of novel targets, immune-based therapies such as CAR T-cell therapy, and utilizing measurable residual disease as a prognostic indicator.
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates
The content of VJHemOnc is intended for healthcare professionals